Tuberculosis control: Challenges of an ancient and ongoing epidemic

Public Health Reports

Volumn 122, Issue 5, 2007, Pages 683-692

  Cummings, Kristin J ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; BCG VACCINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; MVA85A VACCINE; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; R 20791; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SUBUNIT VACCINE; TUBERCULIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIQUITY; BCG VACCINATION; DEVELOPING COUNTRY; DIRECTLY OBSERVED THERAPY; EPIDEMIC; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMIGRANT; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; POLITICS; POVERTY; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES; WORLD HEALTH ORGANIZATION; ARTICLE; COOPERATION; HISTORY; PREVENTIVE MEDICINE; PUBLIC HEALTH;

ANTIBIOTICS, ANTITUBERCULAR; COOPERATIVE BEHAVIOR; DEVELOPING COUNTRIES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PREVENTIVE MEDICINE; PUBLIC HEALTH; TUBERCULOSIS; UNITED STATES;

EID: 35148892218     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335490712200517     Document Type: Review

References (74)

1. Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials 1994;15:247-276
2. Aronson JD, Aronson CF, Taylor HC. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. AMA Arch Intern Med 1958;101:881-893
3. Schatz A, Waksman SA. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Expt Biol and Med 1944;57:244-248
4. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-782
5. Lehman J. Para-amino salicylic acid in the treatment of pulmonary tuberculosis. Lancet 1946;1:15-16
6. Daniel TM. Captain of death: the story of tuberculosis. Rochester (NY): University of Rochester Press; 1997. p. 217-220
7. Tuberculosis Chemotherapy Centre. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Org 1959;21:51-144.
8. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid: a Medical Research Council investigation. Br Med J 1950;2:1073-1085
9. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J Suppl 2002;36:87S-94S.
10. Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials. Am Rev Respir Dis 1973;107:177-190
11. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-79.
12. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12. (Pubitemid 9243249)
13. Hong Kong Chest Service, British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 1982;63:89-98.
14. Lincoln EM. The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 1954;69:682-689
15. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106.
16. American Thoracic Society. Chemoprophylaxis for the prevention of tuberculosis: a statement by an Ad Hoc Committee. Am Rev Respir Dis 1967;96:558-560
17. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972;106:357-365
18. American Thoracic Society/Center for Disease Control and Prevention (US). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-47.
19. Navin TR, McNabb SJ, Crawford JT. The continued threat of tuberculosis. Emerg Infect Dis 2002;8:1187. (Pubitemid 35334685)
20. Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990;65:6-24. (Pubitemid 20163859)
21. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-686
22. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550
23. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-235
24. Wendel KA, Sterling TR. Tuberculosis and HIV. AIDS Clin Care 2002;14:9-15.
25. Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994;272:535-539
26. CDC (US). Tuberculosis morbidity among U.S.-born and foreign-born populations-United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51(5):101-104
27. Hadzibegovic DS, Maloney SA, Cookson ST, Oladele A. Determining TB rates and TB case burden for refugees. Int J Tuberc Lung Dis 2005;9:409-414 (Pubitemid 40524032)
28. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-526 (Pubitemid 23053827)
29. Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997;102:164-170 (Pubitemid 27122998)
30. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997;278:833-837
31. World Health Organization. Antituberculosis drug resistance in the world. Report no. 2: prevalence and trends. Geneva: World Health Organization; 2000. WHO/CDS/TB/2000.278.
32. Zaza S, Blumberg HM, Beck-Sague C, Haas WH, Woodley CL, Pineda M, et al. Nosocomial transmission of Mycobacterium tuberculosis: role of health care workers in outbreak propagation. J Infect Dis 1995;172:1542-1549
33. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995;274:945-951
34. American Thoracic Society; CDC (US); Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52(RR-11):1-77.
35. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug- resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-1109
36. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005;293:2732-2739
37. Recommendations for prevention and control of tuberculosis among foreign-born persons. Report of the Working Group on Tuberculosis Among Foreign-Born Persons. MMWR Recomm Rep 1998;47(RR-16):1-29.
38. Binkin NJ, Zuber PL, Wells CD, Tipple MA, Castro KG. Overseas screening for tuberculosis in immigrants and refugees in the United States: current status. Clin Infect Dis 1996;23:1226-1232 (Pubitemid 26423156)
39. DeRiemer K, Chin DP, Schecter GF, Reingold AL. Tuberculosis among immigrants and refugees. Arch Intern Med 1998;158:753-760 (Pubitemid 28204660)
40. Wells CD, Zuber PL, Nolan CM, Binkin NJ, Goldberg SV. Tuberculosis prevention among foreign-born persons in Seattle-King County, Washington. Am J Respir Dis Crit Care Med 1997;156:573-577 (Pubitemid 27351997)
41. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25:1107-1116 (Pubitemid 40823787)
42. Goldberg SV, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004;8:76-82. (Pubitemid 38120709)
43. World Health Organization. An expanded DOTS framework for effective tuberculosis control. Geneva: World Health Organization; 2002. WHO/CDS/TB/2002.297.
44. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization; 2003. WHO/CDS/TB/2003.313.
45. World Health Organization. Tuberculosis [cited 2007 Jun 4]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs104/en
46. Kim JY, Mukherjee JS, Rich ML, Mate K, Bayona J, Becerra MC. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis (Edinb) 2003;83:59-65. (Pubitemid 36683550)
47. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community-based therapy for multidrug resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-128 (Pubitemid 36056718)
48. Stop TB Working Group on DOTS-Plus for MDR-TB. A prioritized research agenda for DOTS-Plus for multidrug resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003;7:410-414
49. Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE, et al. Public health. Responding to market failures in tuberculosis. Science 2001;293:1049-1051
50. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006;55(43):1176.
51. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999;3:457-465 (Pubitemid 29260156)
52. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501-507
53. Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis 2005;9:270-275 (Pubitemid 40392941)
54. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005;293:2719-2725
55. McNabb SJ, Braden CR, Navin TR. DNA fingerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future. Emerg Infect Dis 2002;8:1314-1319 (Pubitemid 35334708)
56. Northrup JM, Miller AC, Nardell E, Sharnprapai S, Etkind S, Driscoll J, et al. Estimated costs of false laboratory diagnoses of tuberculosis in three patients. Emerg Infect Dis 2002;8:1264-1270
57. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, et al. The epidemiology of tuberculosis in San Francisco. A population- based study using conventional and molecular methods. N Engl J Med 1994;330:1703-1709
58. Moore DF, Guzman JA, Mikhail LT. Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test. Diagn Microbiol Infect Dis 2005;52:247-254 (Pubitemid 41133551)
59. Noordhoek GT, Mulder S, Wallace P, van Loon AM. Multicentre quality control study for detection of Mycobacterium tuberculosis in clinical samples by nucleic amplification methods. Clin Microbiol Infect 2004;10:295-301. (Pubitemid 38519355)
60. Kambashi B, Mbulo G, McNerney R, Tembwe R, Kambashi A, Tihon V, et al. Utility of nucleic acid amplification techniques for the diagnosis of pulmonary tuberculosis in sub-Saharan Africa. Int J Tuberc Lung Dis 2001;5:364-369
61. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Netchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15):49-55.
62. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-776 (Pubitemid 39574348)
63. Barnes PF. Weighing gold or counting spots: which is more sensitive to diagnose latent tuberculosis infection? Am J Respir Crit Care Med 2006;174:731-732
64. O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005;26:327-340 (Pubitemid 40503262)
65. Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 2006;43:1468-1475
66. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-185
67. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227
68. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294-2301
69. Friedrich MJ. Basic science guides design of new TB vaccine candidates. JAMA 2005;293:2703-2705
70. Fruth U, Young D. Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development. Int J Tuberc Lung Dis 2004;8:151-155
71. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005;85:47-52. (Pubitemid 40431315)
72. TB Alliance Portfolio: Nitroimidazole PA-824. June 2007 [cited 2007 Jun 4]. Available from: URL: http://72.3.224.152/new/portfolio/ html-portfolio-item. php?id=18
73. World Health Organization. Fifty-third World Health Assembly: Stop Tuberculosis initiative. Report by the Director-General. A53/5; 5 May 2000. Geneva: World Health Organization; 2000.
74. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-2775 (Pubitemid 40965089)